scholarly journals Pre‐amyloid stage of Alzheimer's disease in cognitively normal individuals

2018 ◽  
Vol 5 (9) ◽  
pp. 1037-1047 ◽  
Author(s):  
Betty M. Tijms ◽  
Lisa Vermunt ◽  
Marissa D. Zwan ◽  
Argonde C. Harten ◽  
Wiesje M. Flier ◽  
...  
2019 ◽  
Vol 15 (6) ◽  
pp. 764-775 ◽  
Author(s):  
Andrea Vergallo ◽  
Lucile Mégret ◽  
Simone Lista ◽  
Enrica Cavedo ◽  
Henrik Zetterberg ◽  
...  

2006 ◽  
Vol 14 (7S_Part_8) ◽  
pp. P478-P479
Author(s):  
Alexa Pichet Binette ◽  
Etienne Vachon-Presseau ◽  
Julie Gonneaud ◽  
Natalie L. Marchant ◽  
Pierre Bellec ◽  
...  

SLEEP ◽  
2020 ◽  
Author(s):  
Jessica E Owen ◽  
Bryndis Benediktsdottir ◽  
Elizabeth Cook ◽  
Isleifur Olafsson ◽  
Thorarinn Gislason ◽  
...  

Abstract Obstructive sleep apnea (OSA) involves intermittent cessations of breathing during sleep. People with OSA can experience memory deficits and have reduced hippocampal volume; these features are also characteristic of Alzheimer’s disease (AD), where they are accompanied by neurofibrillary tangles (NFTs) and amyloid beta (Aβ) plaques in the hippocampus and brainstem. We have recently shown reduced hippocampal volume to be related to OSA severity, and although OSA may be a risk factor for AD, the hippocampus and brainstems of clinically verified OSA cases have not yet been examined for NFTs and Aβ plaques. The present study used quantitative immunohistochemistry to investigate postmortem hippocampi of 34 people with OSA (18 females, 16 males; mean age 67 years) and brainstems of 24 people with OSA for the presence of NFTs and Aβ plaques. OSA severity was a significant predictor of Aβ plaque burden in the hippocampus after controlling for age, sex, body mass index (BMI), and continuous positive airway pressure (CPAP) use. OSA severity also predicted NFT burden in the hippocampus, but not after controlling for age. Although 71% of brainstems contained NFTs and 21% contained Aβ plaques, their burdens were not correlated with OSA severity. These results indicate that OSA accounts for some of the “cognitively normal” individuals who have been found to have substantial Aβ burdens, and are currently considered to be at a prodromal stage of AD.


2016 ◽  
Vol 22 (10) ◽  
pp. 968-977 ◽  
Author(s):  
Anja Soldan ◽  
Corinne Pettigrew ◽  
Abhay Moghekar ◽  
Marilyn Albert ◽  

AbstractObjectives: Evidence suggests that Alzheimer’s disease (AD) biomarkers become abnormal many years before the emergence of clinical symptoms of AD, raising the possibility that biomarker levels measured in cognitively normal individuals would be associated with cognitive performance many years later. This study examined whether performance on computerized cognitive tests is associated with levels of cerebrospinal fluid (CSF) biomarkers of amyloid, tau, and phosphorylated tau (p-tau) obtained approximately 10 years earlier, when individuals were cognitively normal and primarily middle-aged. Methods: Individuals from the BIOCARD cohort (mean age at testing=69 years) were tested on two computerized tasks hypothesized to rely on brain regions affected by the early accumulation of AD pathology: (1) a Paired Associates Learning (PAL) task (n=67) and (2) a visual search task (n=86). Results: In regression analyses, poorer performance on the PAL task was associated with higher levels of CSF p-tau obtained years earlier, whereas worse performance in the visual search task was associated with lower levels of CSF Aβ1-42. Conclusions: These findings suggest that AD biomarker levels may be differentially predictive of specific cognitive functions many years later. In line with the pattern of early accumulation of AD pathology, the PAL task, hypothesized to rely on medial temporal lobe function, was associated with CSF p-tau, whereas the visual search task, hypothesized to rely on frontoparietal function, was associated with CSF amyloid. Studies using amyloid and tau PET imaging will be useful in examining these hypothesized relationships further. (JINS, 2016, 22, 968–977)


2014 ◽  
Vol 04 (02) ◽  
pp. 15-26 ◽  
Author(s):  
John Murray ◽  
Wai H. Tsui ◽  
Yi Li ◽  
Pauline McHugh ◽  
Schantel Williams ◽  
...  

2020 ◽  
Vol 19 ◽  
pp. 153601212094758 ◽  
Author(s):  
Chanisa Chotipanich ◽  
Monchaya Nivorn ◽  
Anchisa Kunawudhi ◽  
Chetsadaporn Promteangtrong ◽  
Natphimol Boonkawin ◽  
...  

Background: The study aimed to evaluate the appropriate uptake-timing in cognitively normal individuals, mild cognitive impairment (MCI), and Alzheimer’s disease (AD) patients, using 18F-PI 2620 dynamic PET acquisition. Methods: Thirty-four MCI patients, 6 AD patients, and 24 cognitively normal individuals were enrolled in this study. A dynamic 18F-PI 2620 PET study was conducted at 30-75 minutes post-injection in these groups. Co-registration was applied between the dynamic acquisition PET and T1-weighted MRI to delineate various cortical regions. The standardized uptake value ratio (SUVR) was used for quantitative analysis. P-mod software with the Automated Anatomical Labeling (AAL)-merged atlas was employed to generate automatic volumes of interest for 11 brain regions. Results: The curves in most brain regions presented an average SUVR stability at 30-40 minutes post-injection in each group. The appropriate uptake-timing interval of 18F-PI 2620 was 30-75 minutes post injection for AD group and 30-40 minutes post injection for both cognitively normal individuals and MCI groups. Conclusion: Short uptake time around 30-40 minutes post-injection would be more comfortable and convenient for all patients, especially in those with dementia who were unable to stay motionless for long periods of scanning time in the scanner.


Sign in / Sign up

Export Citation Format

Share Document